Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Snake venom is a complex mixture of proteins, peptides, and other molecules produced by the venom glands of snakes. It serves primarily for prey immobilization, predigestion, and defense, acting via diverse mechanisms such as neurotoxicity, cytotoxicity, and hemostatic disruption. Snake venoms have been extensively studied for their biomedical potential, yielding drugs for hypertension, thromboembolic disorders, acute coronary syndromes, and chronic pain, among others. Key therapeutic challenges include compositional variability, difficulty of standardization, and inherent toxicity. While the whole venom is not a target, many individual toxin components have been successfully developed into life-saving therapeutics[1][2][3][7].
Enzyme (ACE) inhibition (e.g., captopril) - Glycoprotein IIb/IIIa antagonism (e.g., tirofiban, eptifibatide) - Defibrinogenation (e.g., ancrod, batroxobin) - Direct thrombin inhibition - Modulation of immune response - Inhibition of platelet aggregation - Cytolysis and apoptosis induction in cancer cells[1][7]
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snake venom.